drugset / Trial / NCT02040428

The Fibrin Pad CV Phase III Study

NCT02040428

Phase 3 Completed 156 enrolled Ethicon, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.

Timeline

Start
2014-01-01
Primary completion
2015-07-01
Completion
2015-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject EVARREST™ Fibrin Sealant Patch Protein / enzyme biologic
Comparator Equine collagen Protein / enzyme biologic
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic
Comparator Human Thrombin Protein / enzyme biologic